Computational Drug Development 2016

Computational Drug Development 2016 is organized by Hanson Wade and would be held during Dec 13 - 15, 2016 at Aloft Boston Seaport, Massachusetts, United States of America.

Computational tools have the ability to add tangible value to the development of biologic drugs. When utilized effectively, computational techniques can shorten timelines and enhance the cost-effectiveness of biologic drug development.

Computational Drug Development 2016 will bridge the gap between the application of computational tools for small molecule and biologic drug development. This meeting will bring together leading computational scientists from pharma, biotech, academia and software companies to evolve new solutions to focus the growing computational power on the richly accessible information generated in discovery and development.

10 Reasons to Attend Computational Drug Development 2016 :
• Investigate how computational tools can optimize the manufacturability and physical properties of biotherapeutics
• Successfully integrate computational and experimental methods to improve the success rate of drug development
• Use predictive computational tools to optimize the developability of biologics early in drug discovery
• Gain invaluable insights into how informatics, modeling and simulation can overcome key challenges encountered in the development of biologics
• Benchmark against the leaders in the field to understand how they have effectively integrated in-house and commercially available computational tools into their biologics development workflow
• Discuss how the field can leverage the wealth of computational insights gained in small molecule drug development to impact the development of biologics successfully
• Beyond monoclonal antibodies: Understand how computational tools can improve the development of bispecifics, peptides, vaccines and mRNA-based therapeutics
• Reduce development costs by designing and selecting lead candidates more efficiently
• Utilize bioinformatics tools to map out target recognition sites and enhance structure-based biologic drug design
• Examine real-world case studies detailing how the use of MD simulations, in silico affinity maturation and computational structural modeling have enhanced experimental design

Prices:
Industry - Conference + 2 Workshops: USD 3797,
Industry - Conference + 1 Workshop: USD 3198,
Industry - Conference Only: USD 2699,
Industry - Workshop Only: USD 699,
Academic - Conference + 2 Workshops: USD 2397,
Academic - Conference + 1 Workshop: USD 1998,
Academic - Conference Only: USD 1599,
Academic - Workshop Only : USD 499

Speakers : Sandeep Kumar Head, Molecular Modeling, Simulations and Data Analyses Center of Emphasis, Biotherapeutics Pharmaceutical Sciences, Pfizer, Joseph Audie CEO and CSO CMDBioscience, Chris Bailey-Kellog Professor Dartmouth College, Rafael Depetris Director Molecular Oncology Kadmon Pharmaceuticals, Surjit Dixit CTO Zymeworks, Feng Dong Senior Scientist Abbvie, Sookhee Ha Senior Research Fellow Merck, Christine Hajdin Investigator Novartis, Philip Kim Associate Professor University of Toronto, Stanley Krystek Senior Principal Scientist Bristol-Myers Squibb, Michelle Lynn Hall Senior Scientist Computational Chemistry Moderna Therapeutics, Eliud Oloo Manager Structure Genomics and Bioinformatics Sanofi Pasteur Biologics, Deepangi Pandit Scientist ll Cell Signalling Technology, Enrico Purisima Team Leader Molecular Modeling NRC Canada, Dominic Ryan Independent Consultant, Brad Sherborne Director Computer-Aided Drug Design Merck, Arvind Sivasubramanian Senior Scientist Computational Biology, Adimab Vanita Sood Global Head of Drug Structure Prediction and Design EMD, Serono Jeffrey Way Senior Staff Scientist Wyss Institute Harvard University

Time: 7:30 am to 4:15 pm